http://www.eurekalert.org/pub_releases/ ... 062216.php
Here's full-text of the paper:A recent meta-analysis in Scientific Reports supports a link between EPA and DHA omega-3 intake and a reduced risk of death by any cause. The meta-analysis included 11 studies involving 371,965 participants and 31,185 death events, with a subset of the studies being used for different analyses.
In the analysis of n-3 LCPUFA intake, there was a 9% reduced risk of all-cause death associated with high versus low omega-3 intake. In the dose-response analysis, an increase in EPA/DHA intake of 300 mg/day was associated with a 6% lower risk of all-cause mortality. These findings suggest that both dietary and circulating n-3 LCPUFA are shown to be significantly associated with reduced risk of all-cause mortality.
According to study author Manfred Eggersdorfer, "The meta-analysis of 11 prospective observational studies demonstrates that each 1% increment of omega-3s in total fatty acids in blood may be associated with a 20% decrease in risk of all-cause mortality. This is an important finding for the potential contribution of adequate omega-3 intake to public health."
N-3 long-chain polyunsaturated fatty acids and risk of all-cause mortality among general populations: a meta-analysis
http://www.nature.com/articles/srep28165
Given all of the recent evidence suggesting that maintenance of a higher omega-3 level may be nueroprotective, this is beginning to look like a "no-brainer" EXCEPT for 4/4 males with a family history of stroke in male relatives. Maintaining higher circulating levels may put this very rare group at risk for cerebral amyloid angiopathy (CAA.) You can learn more here.Conclusions
In summary, this meta-analysis of prospective observational studies suggests that both dietary and circulating n-3 LCPUFA are significantly inversely associated with risk of all-cause mortality. More large prospective studies conducted among individuals with high intakes are needed to address whether there is a nonlinear association. Future well designed primary prevention trials that account for nutrition status, health conditions, and medication usages of participants are also warranted to confirm our findings and those from others.
